DIRECT MEASUREMENT OF PSYCHOPHARMACOLOGIC RESPONSE: EFFECTS OF CHLORPROMAZINE ON MOTOR BEHAVIOR OF RETARDED CHILDRENHOLLIS J. H; ST. OMER V. V.AMER. J. MENT. DEFICIENCY. 1972, Vol 76, Num 4, pp 397-407Article

SYSTEMATIC DESENSITIZATION AND EXPECTANCY IN THE TREATMENT OF SPEAKING ANXIETYWOY J. R; EFRAN J. S.BEHAV. RES. THERAPY. 1972, Vol 10, Num 1, pp 43-49Article

DEPERSONALIZATION AND THE USE OF L.S.D.: A PSYCHODYNAMIC STUDYWALTZER H.AMER. J. PSYCHOANAL. 1972, Vol 32, Num 1, pp 45-52Article

THE RELATIONSHIP BETWEEN PAVOR NOCTURNUS AND ADENOIDSAGRELL I.-G; AXELSSON A.ACTA PAEDOPSYCHIATR. 1972, Vol 39, Num 3, pp 46-53Article

Drug Treatment for Hyperactivity: Controversies, Alternatives, and GuidelinesAXELROD, S; BAILEY, S. L.Exceptional Children Arlington, Va. 1979, Vol 45, Num 7, pp 544-550Article

Une sanction de l'univers carcéral: le prix de la communication pour celui d'un traitementBIJEON, G.Information (L') Psychiatrique Toulouse. 1982, Vol 58, Num 6, espArticle

Hyperkinesis and ChemotherapyCALHOUN, G.Academic Therapy San Rafael, Cal. 1979, Vol 15, Num 2, pp 141-144Article

PROGNOSTIC FACTORS AND OUTCOME IN ASKIN-ROSAI TUMOR: A REVIEW OF 104 PATIENTSLASKAR, Siddhartha; NAIR, Chandrika; MISTRY, Rajesh et al.International journal of radiation oncology, biology, physics. 2011, Vol 79, Num 1, pp 202-207, issn 0360-3016, 6 p.Article

2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemiaWEBER, Donna M; DIMOPOULOS, Meletios A; DELASALLE, Kay et al.Seminars in oncology. 2003, Vol 30, Num 2, pp 243-247, issn 0093-7754, 5 p.Article

Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to AP02L/trail-induced apoptosisEVDOKIOU, Andreas; BOURALEXIS, Stelios; ATKINS, Gerald J et al.International journal of cancer. 2002, Vol 99, Num 4, pp 491-504, issn 0020-7136Article

Phase I trials of pemetrexedFOSSELLA, Frank V; GATZEMEIER, Ulrich.Seminars in oncology. 2002, Vol 29, Num 2, pp 8-16, issn 0093-7754, SUP5Conference Paper

High-dose therapy and immunomodulatory drugs in multiple myelomaBARLOGIE, Bart; SHAUGHNESSY, John; ZANGARI, Maurizio et al.Seminars in oncology. 2002, Vol 29, Num 6, pp 26-33, issn 0093-7754, 8 p., SUP17Article

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescueHAGEMEISTER, Fredrick B.Cancer chemotherapy and pharmacology. 2002, Vol 49, pp S13-S20, issn 0344-5704, SUP1Conference Paper

Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor productionTORTORA, G; BIANCO, R; DAMIANO, V et al.Clinical cancer research. 2000, Vol 6, Num 6, pp 2506-2512, issn 1078-0432Article

Efficacity and pharmacokinetic of all trans retinoic acid (ATRA)/interferon α-2a (INF α-2a) in metastatic renal cell cancerPAULE, B; RUDANT, E; BONHOMME-FAIVRE, L et al.Journal de pharmacie clinique (Paris). 1999, Vol 18, Num 4, pp 318-320, issn 0291-1981Article

Preoperative paclitaxel plus carboplatin for patients with intermediate-risk non-small cell lung cancerRUCKDESCHEL, J. C.Seminars in oncology. 1996, Vol 23, Num 6, pp 62-67, issn 0093-7754, SUP16Conference Paper

Clinical developments in prostate cancer. Satellite symposiumThe Prostate. 1994, issn 0270-4137, 41 p., SUP5Conference Proceedings

Does paclitaxel (Taxol) given after ¹¹¹In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers?MIERS, Laird; LAMBORN, Kathleen; YUAN, Aina et al.Clinical cancer research. 2005, Vol 11, Num 19, pp 7158s-7163s, issn 1078-0432, 2Conference Paper

Adding interferon-α to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumoursPAPE, Ulrich-Frank; WIEDENMANN, Bertram.Cancer treatment reviews. 2003, Vol 29, Num 6, pp 565-569, issn 0305-7372, 5 p.Article

Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistanceMUKANGANYAMA, Stanley; WIDERSTEN, Mikael; NAIK, Yogeshkumar S et al.International journal of cancer. 2002, Vol 97, Num 5, pp 700-705, issn 0020-7136Article

Premenopausal breast cancer: Chemotherapy and endocrine therapySAYER, Herbert G; KATH, Roland; KLICHE, Kay-Oliver et al.Drugs (Basel). 2002, Vol 62, Num 14, pp 2025-2038, issn 0012-6667, 14 p.Article

Eradication of human Non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamideKLASA, R. J; BALLY, M. B; NG, R et al.Clinical cancer research. 2000, Vol 6, Num 6, pp 2492-2500, issn 1078-0432Article

On the inhibitory activities of a new boron compound and ultrasound against the mouse ascites tumourSUR, P; GHOSH, P; BAG, S. P et al.Chemotherapy (Basel). 1999, Vol 45, Num 5, pp 360-369, issn 0009-3157Article

High dose therapy and autologous stem cell transplant does not improve survival compared with continued combination chemotherapy in people at high risk of relapse after initial treatment of advanced Hodgkin's lymphomaREECE, Donna E.Cancer treatment reviews. 2003, Vol 29, Num 6, pp 555-559, issn 0305-7372, 5 p.Article

Double-flash, large-fraction radiation therapy as palliative treatment of malignant superior vena cava syndrome in the elderlyLONARDI, Federico; GIOGA, Gloria; AGUS, Graziella et al.Supportive care in cancer. 2002, Vol 10, Num 2, pp 156-160, issn 0941-4355Article